Abstract:ObjectiveTo construct a recombinant Listeria ivanovii (LI) strain that expressed Mycobacterium tuberculosis (MTB) specific antigen protein as a novel multistage tuberculosis (TB) vaccine candidate, and evaluate the biosafety and immunogenicity in mouse model.MethodsT cell epitopes of four genes related to different stages of MTB infection were fused in series to form an antigen gene, i.e. the multistage antigen gene (named msv). Then msv was inserted into the targeting plasmid that contained LI homologous sequences. Recombinant LI strain was obtained by transfecting LI with targeting plasmid and screening the recombinant LI strain that carried msv in the genome after series of homologous gene recombination processes. The growth rate of the recombinant LI strain in vitro was observed and the expression of target protein was verified by Western blot. The 50% lethal dose (LD 50) of the recombinant strain to C57BL/6 mice was measured. Mice were intravenously inoculated with vaccine candidate in dose of 0.1×LD 50.The serum alanine aminotransferase (ALT) levels, bacterial load in organs, and organ pathological sections before and 1, 2, 3, 5, 7, 14 d after vaccination were used to evaluate the safety of vaccine candidate strain. To analyze the immunogenicity of vaccine candidate strain, mice were intravenously inoculated with LI- msv, LI, and NS respectively. Nine days post immunization, the spleens were isolated under sterile conditions and splenocytes were collected and stimulated. Lyphocytes which secret specific cytokines, interferon (IFN)-γ, tumor necrosis factor (TNF)-α and interleukin (IL)-2 were analyzed by flow cytometry.ResultsA recombinant strain named LI- msv which was capable of expressing the multistage TB antigen protein was successfully constructed. The LD 50 value of LI- msv for C57BL/6 mice (i.v.) was 3.3×10 8 CFU. After intravenously immunized the mice, this strain mainly multiplied in the liver and spleen, and was cleared at 7 d post innoculation. Such infection process caused transient pathological damages of the liver and spleen. Results of flow cytometry showed specific IFN-γ + CD4 + and IFN-γ + CD8 +T lymphocytes were successfully induced in LI -msv immunized mice spleen lymphocytes. The frequency of IFN-γ positive CD4 + and CD8 +T cells was significantly higher than those of vector control group and NS control group ( P<0.005). Additionally, the frequency of specific TNF-α + CD4 + T cell in LI -msv immunized group was significantly higher than that of vector control ( P<0.01) and NS control group ( P<0.005), and TNF-α + CD8 + T cell frequency obviously increased than NS control group ( P<0.005).ConclusionsA novel multistage TB vaccine candidate expressing TB multistage antigen based on LI was successfully constructed. This vaccine candidate is safe and can induce specific cellular immune response to some extent. It is promising to be further studied as a candidate vaccine against tuberculosis.

Immunogenicity and protective efficacy of a attenuated salmonella-Vectored vaccine expressing Esat6 against tuberculosis in mice

Cpg7909 Adjuvant Enhanced Immunogenicity Efficacy In Mice Immunized With Esat6-Ag85a Fusion Protein, But Does Not Confer Significant Protection Against Mycobacterium Tuberculosis Infection

Enhancement Of Antituberculosis Immunity In A Humanized Model System By A Novel Virus-Vectored Respiratory Mucosal Vaccine

[Construction and Evaluation of a Tuberculosis Multistage Vaccine Candidate Based on Recombinant Listeria Ivanovii].

A mucosal vaccine formulation against tuberculosis by exploiting the adjuvant activity of S100A4-A damage-associated molecular pattern molecule

ESAT-6 DNA Vaccine for Mycobacterium Tuberculosis and Its Humoral and T-cell Response As Well As Its Protective Efficacy

Improved Humoral Immunity Against Tuberculosis Esat-6 Antigen By Chimeric Dna Prime And Protein Boost Strategy

Saponin TQL1055 adjuvant-containing vaccine confers protection upon Mycobacterium tuberculosis challenge in mice

Immunogenicity and Protective Efficacy of a Fusion Protein Tuberculosis Vaccine Combining Five Esx Family Proteins

Recombinant Bcg Coexpressing Ag85b, Esat-6 and Mouse-Ifn-Gamma Confers Effective Protection Against Mycobacterium Tuberculosis in C57bl/6 Mice

Novel Recombinant Bcg Coexpressing Ag85b, Esat-6 And Rv2608 Elicits Significantly Enhanced Cellular Immune And Antibody Responses In C57bl/6 Mice

Recombinant Bcg Coexpressing Ag85b, Esat-6 and Rv3620c Elicits Specific Th1 Immune Responses in C57bl/6 Mice

Induction of protective immunity by multiantigenic DNA vaccine delivered in attenuated Salmonella typhimurium against Toxoplasma gondii infection in mice.

Novel recombinant BCG coexpressing Ag85B, ESAT-6 and mouse TNF-α induces significantly enhanced cellular immune and antibody responses in C57BL/6 mice: Recombinant BCG expressing Ag85B-ESAT-6-TNF-α

The cellular immune response and protective efficacy against tuberculosis infection of a novel mycobacterium tuberculosis DNA vaccine p846

Immunogenicity and protective efficacy of novel Mycobacterium tuberculosis antigens

Cationic pH-sensitive liposome-based subunit tuberculosis vaccine induces protection in mice challenged with Mycobacterium tuberculosis

A multistage Sendai virus vaccine incorporating latency-associated antigens induces protection against acute and latent tuberculosis

The Immunogenicity and Safety of Mycobacterium tuberculosis-mosR-Based Double Deletion Strain in Mice

Combined Recombinant DNA Vaccine Results in Significant Protection Against Mycobacterium Tuberculosis

Study on Immunogenicity and Protective Efficacy of Tetravalent Combination M-Tuberculosis Dna Vaccinea